LIFECORE BIOMEDICAL, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures
LIFECORE BIOMEDICAL, INC. (LFCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures of 59.79 thousand shares for the 12-month period ending 2017-05-28, per its 10-K filed 2018-08-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures · last filed 2018-08-09
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2017 was 59.79K shares, a 113.55% increase from fiscal 2016.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2016 was 28.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 12 month |
|---|---|
| 2017-05-28 | 59.79K shares 10-K · filed 2018-08-09 |
| 2016-05-29 | 28.00K shares 10-K/A · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |